1
Christoph Arth, Andreas Kollmeyer Seeger, Stephan Rimpler, Hans Michael Wolff: Transdermal therapeutic system containing pergolide. Schwarz Pharma, Marshall Gerstein & Borun, October 8, 2002: US06461636 (50 worldwide citation)

The invention relates to a transdermal therapeutic system (TTS) for the transcutaneous administration of pergolide over several days and to a method for its manufacture without using solvents. The TTS contains a matrix mass, containing pergolide and taking the form of a layer, which contains a (meth ...


2
Christoph Arth, Claus Meese, Dietrich Wilhelm Schacht, Hans Michael Wolff: Transdermal therapeutic system TTS containing tolterodine. Schwarz Pharma, Peter F Corless, Christine C O&apos Day, Edwards & Angell, August 31, 2004: US06783769 (31 worldwide citation)

The invention relates to a transdermal therapeutic system (TTS) for transcutaneously administering tolterodine over a period of several days and to a method for producing the same. The TTS contains a self-adhesive layer-shaped matrix composition which contains a (meth)acrylate copolymer comprising a ...


3
Hans Michael Wolff, Christoph Arth: Therapeutical system for transdermal delivery of levonorgestrel. Schwarz Pharma, Marshall Gerstein & Borun, April 29, 2003: US06555131 (17 worldwide citation)

A stable therapeutical transdermal system for the transcutaneous delivery of levonorgestrel, alone or together with other sex steroid hormones, over a long time period is disclosed. A method of producing the transdermal system that avoids the use of solvents and avoids degradation of the steroid hor ...


4
Hans P Merkle, Klaus Nagels, Dietrich Schacht, Hans Michael Wolff: Active ingredient patch for low-melting and/or volatile active ingredients. Schwarz Pharma, Marshall O Toole Gerstein Murray & Borun, June 18, 1996: US05527536 (14 worldwide citation)

The invention concerns a patch for the controlled release of readily available volatile active substances to the skin, the patch comprising a back layer and, bonded to it, a water-insoluble adhesive film consisting of a pressure-sensitive fusion adhesive, plus a detachable film covering the adhesive ...


5
Hans Michael Wolff, Christoph Arth: Schwarz Pharma, Marshall Gerstein & Borun, May 13, 2003: US06562367 (14 worldwide citation)

A transdermal therapeutic system for transcutaneous administration of sexual steroid hormones over long time periods, and a solvent-free method for the production thereof, is disclosed. The steroid hormones are subjected to as little thermal exposure as possible, thereby avoiding decomposition of th ...


6
Dieter Beutner, Henning von Knobelsdorff, Hans Michael Wolff, Rainer Hoffmann, Reinhold Meconi, Robert P Klein: Nitroglycerine plaster and process for its production. Schwarz Pharma, LTS Lohmann Therapie Systemme & Co KG, Meltzer Lippe Goldstein et al, March 12, 1996: US05498418 (7 worldwide citation)

The invention relates to a dermal plaster for the transdermal provision of nitroglycerin comprising a carrier film and a removable protective film and an adhesive mass containing nitroglycerine on the basis of a cross-linked acrylate-vinyl acetate copolymer in which the monomer mix used for polymeri ...


7
Dietrich Wilhelm Schacht, Mike Hannay, Hans Michael Wolff: Transdermal delivery system for the administration of rotigotine. UCB Pharma, Harness Dickey & Pierce, December 31, 2013: US08617591 (5 worldwide citation)

An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid sem ...


8
Gai Ling Li, Johanna Aaltje Bouwstra, Hans Michael Wolff, Akhmad Karis Nugroho: Iontophoretic delivery of rotigotine for the treatment of Parkinsons disease. Schwarz Pharma, Harness Dickey & Pierce, December 15, 2009: US07632859 (3 worldwide citation)

By using a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5 in a iontophoretic device for the treatment of Parkinson's disease, it became possible to obtain a rotigotine flux across the human stratum corne ...


9
Armin Breitenbach, Hans Michael Wolff: Hot-melt TTS for administering rotigotine. UCB Pharma, Harness Dickey & Pierce, July 3, 2012: US08211462 (3 worldwide citation)

This patent application relates to a transdermal therapeutic system (TTS) that comprises a Rotigotine-containing cement layer, characterized in that the cement layer contains a hot-meltable adhesive in which Rotigotine as the active substance is dispersed and partly or completely dissolved. The pate ...


10
Christoph Arth, Andreas Kollmeyer Seeger, Stephan Rimpler, Hans Michael Wolff: Transdermal therapeutic system (TTS) containing oxybutynin. Schwarz Pharma, Marshall Gerstein & Borun, April 29, 2003: US06555129 (3 worldwide citation)

A transdermal therapeutic system (TTS) for transcutaneous administration of oxybutynin over a period of several days, in addition to a method for the production of the TTS without the use of solvents, are disclosed. The TTS contains a matrix mass containing oxybutynin in the form of a self-adhesive ...